GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition

Background: Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no anti-fibrotic drugs licensed for human use. Here, we investigated the anti-fibrotic activity of GNS561, a new lysosomotropic molecule with high live...

Full description

Saved in:
Bibliographic Details
Published inTherapeutic advances in chronic disease Vol. 11; p. 2040622320942042
Main Authors Bestion, Eloïne, Jilkova, Zuzana Macek, Mège, Jean-Louis, Novello, Marie, Kurma, Keerthi, Pour, Seyedeh Tayebeh Ahmad, Lalmanach, Gilles, Vanderlynden, Lise, Fizanne, Lionel, Bassissi, Firas, Rachid, Madani, Tracz, Jennifer, Boursier, Jérôme, Courcambeck, Jérôme, Serdjebi, Cindy, Ansaldi, Christelle, Decaens, Thomas, Halfon, Philippe, Brun, Sonia
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 2020
SAGE PUBLICATIONS, INC
Sage
SAGE Publishing
Subjects
Autophagy
Biochemistry, Molecular Biology
Cellular biology
Inhibitor drugs
Life Sciences
Liver
Liver cirrhosis
Liver diseases
Original Research
lysosomotropism
TGF-β1
liver fibrosis
autophagy
cathepsin
GNS561
Online AccessGet full text
ISSN2040-6223
2040-6231
DOI10.1177/2040622320942042

Cover

Abstract Background: Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no anti-fibrotic drugs licensed for human use. Here, we investigated the anti-fibrotic activity of GNS561, a new lysosomotropic molecule with high liver tropism. Methods: The anti-fibrotic effect of GNS561 was determined in vitro using LX-2 hepatic stellate cells (HSCs) and primary human HSCs by studying cell viability, activity of caspases 3/7, autophagic flux, cathepsin maturation and activity, HSC activation and transforming growth factor-β1 (TGF-β1) maturation and signaling. The contribution of GNS561 lysosomotropism to its anti-fibrotic activity was assessed by increasing lysosomal pH. The potency of GNS561 on fibrosis was evaluated in vivo in a rat model of diethylnitrosamine-induced liver fibrosis. Results: GNS561 significantly decreased cell viability and promoted apoptosis. Disrupting the lysosomal pH gradient impaired its pharmacological effects, suggesting that GNS561 lysosomotropism mediated cell death. GNS561 impaired cathepsin activity, leading to defective TGF-β1 maturation and autophagic processes. Moreover, GNS561 decreased HSC activation and extracellular matrix deposition by downregulating TGF-β1/Smad and mitogen-activated proteine kinase signaling and inducing fibrolysis. Finally, oral administration of GNS561 (15 mg/kg per day) was well tolerated and attenuated diethylnitrosamine-induced liver fibrosis in this rat model (decrease of collagen deposition and of pro-fibrotic markers and increase of fibrolysis). Conclusion: GNS561 is a new potent lysosomotropic compound that could represent a valid medicinal option for hepatic fibrosis treatment through both its anti-fibrotic and its pro-fibrolytic effects. In addition, this study provides a rationale for targeting lysosomes as a promising therapeutic strategy in liver fibrosis.
AbstractList Background: Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no anti-fibrotic drugs licensed for human use. Here, we investigated the anti-fibrotic activity of GNS561, a new lysosomotropic molecule with high liver tropism. Methods: The anti-fibrotic effect of GNS561 was determined in vitro using LX-2 hepatic stellate cells (HSCs) and primary human HSCs by studying cell viability, activity of caspases 3/7, autophagic flux, cathepsin maturation and activity, HSC activation and transforming growth factor-β1 (TGF-β1) maturation and signaling. The contribution of GNS561 lysosomotropism to its anti-fibrotic activity was assessed by increasing lysosomal pH. The potency of GNS561 on fibrosis was evaluated in vivo in a rat model of diethylnitrosamine-induced liver fibrosis. Results: GNS561 significantly decreased cell viability and promoted apoptosis. Disrupting the lysosomal pH gradient impaired its pharmacological effects, suggesting that GNS561 lysosomotropism mediated cell death. GNS561 impaired cathepsin activity, leading to defective TGF-β1 maturation and autophagic processes. Moreover, GNS561 decreased HSC activation and extracellular matrix deposition by downregulating TGF-β1/Smad and mitogen-activated proteine kinase signaling and inducing fibrolysis. Finally, oral administration of GNS561 (15 mg/kg per day) was well tolerated and attenuated diethylnitrosamine-induced liver fibrosis in this rat model (decrease of collagen deposition and of pro-fibrotic markers and increase of fibrolysis). Conclusion: GNS561 is a new potent lysosomotropic compound that could represent a valid medicinal option for hepatic fibrosis treatment through both its anti-fibrotic and its pro-fibrolytic effects. In addition, this study provides a rationale for targeting lysosomes as a promising therapeutic strategy in liver fibrosis.
Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no anti-fibrotic drugs licensed for human use. Here, we investigated the anti-fibrotic activity of GNS561, a new lysosomotropic molecule with high liver tropism.BACKGROUNDHepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no anti-fibrotic drugs licensed for human use. Here, we investigated the anti-fibrotic activity of GNS561, a new lysosomotropic molecule with high liver tropism.The anti-fibrotic effect of GNS561 was determined in vitro using LX-2 hepatic stellate cells (HSCs) and primary human HSCs by studying cell viability, activity of caspases 3/7, autophagic flux, cathepsin maturation and activity, HSC activation and transforming growth factor-β1 (TGF-β1) maturation and signaling. The contribution of GNS561 lysosomotropism to its anti-fibrotic activity was assessed by increasing lysosomal pH. The potency of GNS561 on fibrosis was evaluated in vivo in a rat model of diethylnitrosamine-induced liver fibrosis.METHODSThe anti-fibrotic effect of GNS561 was determined in vitro using LX-2 hepatic stellate cells (HSCs) and primary human HSCs by studying cell viability, activity of caspases 3/7, autophagic flux, cathepsin maturation and activity, HSC activation and transforming growth factor-β1 (TGF-β1) maturation and signaling. The contribution of GNS561 lysosomotropism to its anti-fibrotic activity was assessed by increasing lysosomal pH. The potency of GNS561 on fibrosis was evaluated in vivo in a rat model of diethylnitrosamine-induced liver fibrosis.GNS561 significantly decreased cell viability and promoted apoptosis. Disrupting the lysosomal pH gradient impaired its pharmacological effects, suggesting that GNS561 lysosomotropism mediated cell death. GNS561 impaired cathepsin activity, leading to defective TGF-β1 maturation and autophagic processes. Moreover, GNS561 decreased HSC activation and extracellular matrix deposition by downregulating TGF-β1/Smad and mitogen-activated proteine kinase signaling and inducing fibrolysis. Finally, oral administration of GNS561 (15 mg/kg per day) was well tolerated and attenuated diethylnitrosamine-induced liver fibrosis in this rat model (decrease of collagen deposition and of pro-fibrotic markers and increase of fibrolysis).RESULTSGNS561 significantly decreased cell viability and promoted apoptosis. Disrupting the lysosomal pH gradient impaired its pharmacological effects, suggesting that GNS561 lysosomotropism mediated cell death. GNS561 impaired cathepsin activity, leading to defective TGF-β1 maturation and autophagic processes. Moreover, GNS561 decreased HSC activation and extracellular matrix deposition by downregulating TGF-β1/Smad and mitogen-activated proteine kinase signaling and inducing fibrolysis. Finally, oral administration of GNS561 (15 mg/kg per day) was well tolerated and attenuated diethylnitrosamine-induced liver fibrosis in this rat model (decrease of collagen deposition and of pro-fibrotic markers and increase of fibrolysis).GNS561 is a new potent lysosomotropic compound that could represent a valid medicinal option for hepatic fibrosis treatment through both its anti-fibrotic and its pro-fibrolytic effects. In addition, this study provides a rationale for targeting lysosomes as a promising therapeutic strategy in liver fibrosis.CONCLUSIONGNS561 is a new potent lysosomotropic compound that could represent a valid medicinal option for hepatic fibrosis treatment through both its anti-fibrotic and its pro-fibrolytic effects. In addition, this study provides a rationale for targeting lysosomes as a promising therapeutic strategy in liver fibrosis.
Background: Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no anti-fibrotic drugs licensed for human use. Here, we investigated the anti-fibrotic activity of GNS561, a new lysosomotropic molecule with high liver tropism. Methods: The anti-fibrotic effect of GNS561 was determined in vitro using LX-2 hepatic stellate cells (HSCs) and primary human HSCs by studying cell viability, activity of caspases 3/7, autophagic flux, cathepsin maturation and activity, HSC activation and transforming growth factor-β1 (TGF-β1) maturation and signaling. The contribution of GNS561 lysosomotropism to its anti-fibrotic activity was assessed by increasing lysosomal pH. The potency of GNS561 on fibrosis was evaluated in vivo in a rat model of diethylnitrosamine-induced liver fibrosis. Results: GNS561 significantly decreased cell viability and promoted apoptosis. Disrupting the lysosomal pH gradient impaired its pharmacological effects, suggesting that GNS561 lysosomotropism mediated cell death. GNS561 impaired cathepsin activity, leading to defective TGF-β1 maturation and autophagic processes. Moreover, GNS561 decreased HSC activation and extracellular matrix deposition by downregulating TGF-β1/Smad and mitogen-activated proteine kinase signaling and inducing fibrolysis. Finally, oral administration of GNS561 (15 mg/kg per day) was well tolerated and attenuated diethylnitrosamine-induced liver fibrosis in this rat model (decrease of collagen deposition and of pro-fibrotic markers and increase of fibrolysis). Conclusion: GNS561 is a new potent lysosomotropic compound that could represent a valid medicinal option for hepatic fibrosis treatment through both its anti-fibrotic and its pro-fibrolytic effects. In addition, this study provides a rationale for targeting lysosomes as a promising therapeutic strategy in liver fibrosis.
Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no anti-fibrotic drugs licensed for human use. Here, we investigated the anti-fibrotic activity of GNS561, a new lysosomotropic molecule with high liver tropism. The anti-fibrotic effect of GNS561 was determined using LX-2 hepatic stellate cells (HSCs) and primary human HSCs by studying cell viability, activity of caspases 3/7, autophagic flux, cathepsin maturation and activity, HSC activation and transforming growth factor-β1 (TGF-β1) maturation and signaling. The contribution of GNS561 lysosomotropism to its anti-fibrotic activity was assessed by increasing lysosomal pH. The potency of GNS561 on fibrosis was evaluated in a rat model of diethylnitrosamine-induced liver fibrosis. GNS561 significantly decreased cell viability and promoted apoptosis. Disrupting the lysosomal pH gradient impaired its pharmacological effects, suggesting that GNS561 lysosomotropism mediated cell death. GNS561 impaired cathepsin activity, leading to defective TGF-β1 maturation and autophagic processes. Moreover, GNS561 decreased HSC activation and extracellular matrix deposition by downregulating TGF-β1/Smad and mitogen-activated proteine kinase signaling and inducing fibrolysis. Finally, oral administration of GNS561 (15 mg/kg per day) was well tolerated and attenuated diethylnitrosamine-induced liver fibrosis in this rat model (decrease of collagen deposition and of pro-fibrotic markers and increase of fibrolysis). GNS561 is a new potent lysosomotropic compound that could represent a valid medicinal option for hepatic fibrosis treatment through both its anti-fibrotic and its pro-fibrolytic effects. In addition, this study provides a rationale for targeting lysosomes as a promising therapeutic strategy in liver fibrosis.
Author Pour, Seyedeh Tayebeh Ahmad
Lalmanach, Gilles
Fizanne, Lionel
Rachid, Madani
Halfon, Philippe
Brun, Sonia
Decaens, Thomas
Serdjebi, Cindy
Bestion, Eloïne
Vanderlynden, Lise
Mège, Jean-Louis
Bassissi, Firas
Novello, Marie
Boursier, Jérôme
Tracz, Jennifer
Kurma, Keerthi
Courcambeck, Jérôme
Ansaldi, Christelle
Jilkova, Zuzana Macek
Author_xml – sequence: 1
  givenname: Eloïne
  surname: Bestion
  fullname: Bestion, Eloïne
  organization: Genoscience Pharma, Marseille, France, IRD, MEPHI, IHU Méditerranée Infection, Aix Marseille Université, Marseille, France
– sequence: 2
  givenname: Zuzana Macek
  surname: Jilkova
  fullname: Jilkova, Zuzana Macek
  organization: Institute for Advanced Biosciences, Research Center UGA/Inserm U 1209/CNRS 5309, La Tronche, France Université Grenoble Alpes, Faculté de médecine, France, Clinique Universitaire d’Hépato-gastroentérologie, Pôle Digidune, CHU Grenoble, France
– sequence: 3
  givenname: Jean-Louis
  surname: Mège
  fullname: Mège, Jean-Louis
  organization: IRD, MEPHI, IHU Méditerranée Infection, Aix Marseille Université, Marseille, France
– sequence: 4
  givenname: Marie
  surname: Novello
  fullname: Novello, Marie
  organization: Genoscience Pharma, Marseille, France
– sequence: 5
  givenname: Keerthi
  surname: Kurma
  fullname: Kurma, Keerthi
  organization: Institute for Advanced Biosciences, Research Center UGA/Inserm U 1209/CNRS 5309, La Tronche, France Université Grenoble Alpes, Faculté de médecine, France, Clinique Universitaire d’Hépato-gastroentérologie, Pôle Digidune, CHU Grenoble, France
– sequence: 6
  givenname: Seyedeh Tayebeh Ahmad
  surname: Pour
  fullname: Pour, Seyedeh Tayebeh Ahmad
  organization: Institute for Advanced Biosciences, Research Center UGA/Inserm U 1209/CNRS 5309, La Tronche, France Université Grenoble Alpes, Faculté de médecine, France, Clinique Universitaire d’Hépato-gastroentérologie, Pôle Digidune, CHU Grenoble, France
– sequence: 7
  givenname: Gilles
  surname: Lalmanach
  fullname: Lalmanach, Gilles
  organization: INSERM, UMR1100, Centre d’Etude des Pathologies Respiratoires, Equipe «Mécanismes Protéolytiques dans l’Inflammation», Tours, France, Université de Tours, Tours, France
– sequence: 8
  givenname: Lise
  surname: Vanderlynden
  fullname: Vanderlynden, Lise
  organization: INSERM, UMR1100, Centre d’Etude des Pathologies Respiratoires, Equipe «Mécanismes Protéolytiques dans l’Inflammation», Tours, France, Université de Tours, Tours, France
– sequence: 9
  givenname: Lionel
  surname: Fizanne
  fullname: Fizanne, Lionel
  organization: Laboratoire HIFIH, UPRES EA 3859, Université d’Angers, Angers, France
– sequence: 10
  givenname: Firas
  surname: Bassissi
  fullname: Bassissi, Firas
  organization: Genoscience Pharma, Marseille, France
– sequence: 11
  givenname: Madani
  surname: Rachid
  fullname: Rachid, Madani
  organization: Genoscience Pharma, Marseille, France
– sequence: 12
  givenname: Jennifer
  surname: Tracz
  fullname: Tracz, Jennifer
  organization: Genoscience Pharma, Marseille, France
– sequence: 13
  givenname: Jérôme
  surname: Boursier
  fullname: Boursier, Jérôme
  organization: Laboratoire HIFIH, UPRES EA 3859, Université d’Angers, Angers, France
– sequence: 14
  givenname: Jérôme
  surname: Courcambeck
  fullname: Courcambeck, Jérôme
  organization: Genoscience Pharma, Marseille, France
– sequence: 15
  givenname: Cindy
  surname: Serdjebi
  fullname: Serdjebi, Cindy
  organization: Genoscience Pharma, Marseille, France
– sequence: 16
  givenname: Christelle
  surname: Ansaldi
  fullname: Ansaldi, Christelle
  organization: Genoscience Pharma, Marseille, France
– sequence: 17
  givenname: Thomas
  surname: Decaens
  fullname: Decaens, Thomas
  organization: Institute for Advanced Biosciences, Research Center UGA/Inserm U 1209/CNRS 5309, La Tronche, France Université Grenoble Alpes, Faculté de médecine, France, Clinique Universitaire d’Hépato-gastroentérologie, Pôle Digidune, CHU Grenoble, France
– sequence: 18
  givenname: Philippe
  surname: Halfon
  fullname: Halfon, Philippe
  email: phalfon@genosciencepharma.com
  organization: Genoscience Pharma, 10 Rue d’Iéna, Marseille, 13006, France
– sequence: 19
  givenname: Sonia
  orcidid: 0000-0001-8981-8957
  surname: Brun
  fullname: Brun, Sonia
  email: brun.sonia@hotmail.fr
  organization: Genoscience Pharma, 10 Rue d’Iéna, Marseille, 13006, France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32728410$$D View this record in MEDLINE/PubMed
https://univ-tours.hal.science/hal-02977880$$DView record in HAL
BookMark eNp9ks1u1DAUhS1UREvpnhWKxKYsAv63s0GqKjqtNIIFZW3ZjjPxkIkHOxmpr8WD8Ew4k7bQkSCyFPv4u8e-vvclOOpD7wB4jeB7hIT4gCGFHGOCYUXzHD8DJ5NUckzQ0eMck2NwltIa5o9yQqh8AY4JFlhSBE_A98Xnr4yjQtshFTqPYhsG1w-F7gdfNt7EMHibV3WxjWEWuru9tJow3xed37lY7HeST8XQxjCu2uJ2cVX--oky0XrjBx_6V-B5o7vkzu7_p-Db1afby-ty-WVxc3mxLC0VApdSQkvqhjuBCGcC4YrUvKKWWUyppVAIg4WRhklGmKgkEpoyQ6VFyBptNTkFN7NvHfRabaPf6HingvZqL4S4UjrmFDqnUIMtbVhjEeOUYWOYJYbWDSYua4hnr4-z13Y0G1fbnHPU3RPTpzu9b9Uq7JQgnFOIssG72aA9CLu-WKpJg7gSIue8m9jz-8Ni-DG6NKiNT9Z1ne5dGJPCFFeQSYKqjL49QNdhjH1-1kxRzCSSgmbqzd-3fzz_of4Z4DNgc_FSdI2yftBTsXIyvlMIqqnX1GGv5UB4EPjg_Z-Qcg5JuXX-XPef_G9IQN6K
CitedBy_id crossref_primary_10_3390_cancers13194981
crossref_primary_10_3390_ph17121724
crossref_primary_10_3390_ijms24119671
crossref_primary_10_1016_j_canlet_2023_216599
crossref_primary_10_37349_edd_2023_00013
crossref_primary_10_1080_15548627_2021_1988357
crossref_primary_10_3389_fphar_2021_618846
crossref_primary_10_3390_v14010132
Cites_doi 10.1016/j.hbpd.2018.04.003
10.1111/j.1440-1746.2006.04584.x
10.1002/hep.22753
10.1016/j.jhep.2011.07.010
10.1074/jbc.M102382200
10.1074/jbc.M311668200
10.18632/oncotarget.24298
10.1016/j.tips.2017.06.003
10.1016/j.tox.2008.06.013
10.1016/j.jhep.2019.01.026
10.1038/nature25501
10.3748/wjg.v22.i1.72
10.1369/0022155415627681
10.3390/cells8111419
10.1515/hsz-2014-0210
10.1016/j.jhep.2018.09.014
10.1074/jbc.M111.272393
10.1016/j.matbio.2017.12.012
10.2147/MNM.S124363
10.1111/j.1478-3231.2009.02070.x
10.1016/j.biochi.2010.05.009
10.1038/s41598-017-09673-5
10.1002/hep.20538
10.1111/j.1440-1746.2006.04586.x
10.1172/JCI200317740
10.1158/1535-7163.MCT-18-0850
10.1136/gut.2005.088690
10.1007/s40265-019-01126-9
10.1007/s00204-015-1543-4
10.1016/j.cytogfr.2005.09.008
10.1007/s00441-011-1246-y
10.1016/j.matbio.2015.03.005
10.1002/0471141755.ph1430s66
10.1053/j.gastro.2011.12.044
10.1016/j.jhep.2007.02.003
10.1016/j.addr.2017.05.007
10.1074/jbc.273.50.33533
10.4161/auto.8.1.18105
10.1038/nrneph.2016.48
10.1136/gut.2004.042127
10.1053/jhep.2002.35279
10.2741/A812
10.3109/08977194.2011.595714
10.1055/s-2001-17558
10.1074/jbc.M113.542407
10.1007/s10637-019-00741-3.
10.1053/jhep.2003.50002
10.1016/S1286-4579(99)00259-2
10.1111/febs.13665
10.14218/JCTH.2014.00035
ContentType Journal Article
Copyright The Author(s), 2020
The Author(s), 2020.
The Author(s), 2020. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Distributed under a Creative Commons Attribution 4.0 International License
The Author(s), 2020 2020 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
Copyright_xml – notice: The Author(s), 2020
– notice: The Author(s), 2020.
– notice: The Author(s), 2020. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Distributed under a Creative Commons Attribution 4.0 International License
– notice: The Author(s), 2020 2020 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
DBID AFRWT
AAYXX
CITATION
NPM
3V.
7RV
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
NAPCQ
PHGZM
PHGZT
PIMPY
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
1XC
5PM
DOA
DOI 10.1177/2040622320942042
DatabaseName Open Access资源_Sage Open Access Journals @sage主站点
CrossRef
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
Hyper Article en Ligne (HAL)
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals (WRLC)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

PubMed
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2040-6231
ExternalDocumentID oai_doaj_org_article_1f2c4f5fc156452bb5c3b4df23efc116
PMC7366401
oai_HAL_hal_02977880v1
32728410
10_1177_2040622320942042
10.1177_2040622320942042
Genre Journal Article
GroupedDBID ---
01A
0R~
4.4
53G
54M
5VS
7RV
7X7
8FI
8FJ
AAKDD
AARIX
AASGM
ABAFQ
ABAWP
ABJIS
ABQXT
ABRHV
ABUWG
ABVFX
ABXGC
ACARO
ACDXX
ACGFS
ACROE
ADBBV
ADEBD
ADOGD
ADZYD
AERKM
AEUHG
AEWDL
AFCOW
AFKRA
AFKRG
AFRWT
AFUIA
AGNHF
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ARTOV
AUTPY
AYAKG
BAWUL
BCNDV
BDDNI
BENPR
BKEYQ
BKSCU
BPHCQ
BSEHC
BVXVI
CAG
CCPQU
COF
DC.
DIK
EBS
EJD
EMOBN
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
GX1
H13
HMCUK
HYE
HZ~
J8X
K.F
N9A
NAPCQ
O9-
OK1
P.B
PHGZM
PHGZT
PIMPY
PQQKQ
ROL
RPM
S01
SAUOL
SCDPB
SCNPE
SFC
UKHRP
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
ACHEB
CITATION
31X
AADTT
AATBZ
ABHQH
ACGZU
ACSBE
ACSIQ
ACTQU
ACUIR
AEUIJ
AEWHI
B8Z
DV7
M4V
NPM
SFK
SFT
SGV
SPJ
SPP
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
PUEGO
1XC
5PM
ID FETCH-LOGICAL-c4772-880c3df6e7136571293d694c5c244c4077b27b8b5853579817a45b48c11cbaca3
IEDL.DBID DOA
ISSN 2040-6223
IngestDate Wed Aug 27 01:29:55 EDT 2025
Thu Aug 21 17:56:08 EDT 2025
Fri May 09 12:21:03 EDT 2025
Thu Sep 04 23:16:38 EDT 2025
Sat Jul 26 00:15:59 EDT 2025
Wed Feb 19 02:27:27 EST 2025
Tue Jul 01 05:23:52 EDT 2025
Thu Apr 24 23:06:49 EDT 2025
Tue Jun 17 22:31:00 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords lysosomotropism
TGF-β1
liver fibrosis
autophagy
cathepsin
GNS561
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
The Author(s), 2020.
Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4772-880c3df6e7136571293d694c5c244c4077b27b8b5853579817a45b48c11cbaca3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMCID: PMC7366401
These authors contributed equally to this work
ORCID 0000-0001-8981-8957
0000-0003-3250-1072
0000-0001-8562-4821
0000-0003-0928-0048
0000-0001-5870-3428
0000-0002-2553-5971
OpenAccessLink https://doaj.org/article/1f2c4f5fc156452bb5c3b4df23efc116
PMID 32728410
PQID 2442581874
PQPubID 4450848
ParticipantIDs doaj_primary_oai_doaj_org_article_1f2c4f5fc156452bb5c3b4df23efc116
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7366401
hal_primary_oai_HAL_hal_02977880v1
proquest_miscellaneous_2429058319
proquest_journals_2442581874
pubmed_primary_32728410
crossref_citationtrail_10_1177_2040622320942042
crossref_primary_10_1177_2040622320942042
sage_journals_10_1177_2040622320942042
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-00-00
PublicationDateYYYYMMDD 2020-01-01
PublicationDate_xml – year: 2020
  text: 2020-00-00
PublicationDecade 2020
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: United States
– name: Thousand Oaks
– name: Sage UK: London, England
PublicationTitle Therapeutic advances in chronic disease
PublicationTitleAlternate Ther Adv Chronic Dis
PublicationYear 2020
Publisher SAGE Publications
SAGE PUBLICATIONS, INC
Sage
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: SAGE PUBLICATIONS, INC
– name: Sage
– name: SAGE Publishing
References Moles, Tarrats, Fernandez-Checa 2009; 49
Roberts, Tian, Byfield 2006; 17
Han 2006; 21
Hemmann, Graf, Roderfeld 2007; 46
Taimr, Higuchi, Kocova 2003; 37
Hernandez-Gea, Ghiassi-Nejad, Rozenfeld 2012; 142
Wu, Zhang, Mo 2017; 7
Schiffer, Housset, Cacheux 2005; 41
Mariathasan, Turley, Nickles 2018; 554
Khalil 1999; 1
Thoen, Guimaraes, Dolle 2011; 55
Lalmanach, Saidi, Marchand-Adam 2015; 396
Kramer, Turk, Turk 2017; 38
Allaire, Rautou, Codogno 2019; 70
Hartland, Murphy, Aucott 2009; 29
Brun, Bassissi, Serdjebi
Dooley, ten Dijke 2012; 347
Arpino, Brock, Gill 2015; 44–46
Delire, Starkel, Leclercq 2015; 3
Kasabova, Joulin-Giet, Lecaille 2014; 289
Ezhilarasan, Sokal, Najimi 2018; 17
Dewidar, Meyer, Dooley 2019 1419; 8
Zbodakova, Chalupsky, Tureckova 2017; 2017
Zhou, Murphy, Gehdu 2004; 279
Fabregat, Moreno-Caceres, Sanchez 2016; 283
Oliver, de la Rubia, Rolli 1998; 273
Meng, Nikolic-Paterson, Lan 2016; 12
Asrani, Devarbhavi, Eaton 2019; 70
Biernacka, Dobaczewski, Frangogiannis 2011; 29
Dietrich, Gotze, Geier 2016; 22
Roeb 2018; 68–69
Kisseleva, Brenner 2006; 21
Inagaki, Okazaki 2007; 56
Thoen, Guimaraes, Grunsven 2012; 8
Yanguas, Cogliati, Willebrords 2016; 90
Canbay, Guicciardi, Higuchi 2003; 112
Uehara, Pogribny, Rusyn 2014; 66
Xu, Liu, Zhou 2016; 64
Moles, Tarrats, Fernandez-Checa 2012; 287
Masson, Bach, Derocq 2010; 92
Manka, Zeller, Syn 2019; 79
Higashi, Friedman, Hoshida 2017; 121
Preaux, D’Ortho, Bralet 2002; 36
Jilkova, Kuyucu, Kurma 2018; 9
Principe, Park, Dorman 2019; 18
Gressner, Weiskirchen, Breitkopf 2002; 7
Bataller, Brenner 2001; 21
Friedman 2008; 254
Piek, Ju, Heyer 2001; 276
Xu, Hui, Albanis 2005; 54
bibr28-2040622320942042
bibr6-2040622320942042
bibr10-2040622320942042
bibr7-2040622320942042
bibr37-2040622320942042
bibr44-2040622320942042
bibr35-2040622320942042
bibr29-2040622320942042
bibr38-2040622320942042
bibr51-2040622320942042
bibr8-2040622320942042
bibr43-2040622320942042
bibr47-2040622320942042
bibr34-2040622320942042
bibr9-2040622320942042
bibr21-2040622320942042
bibr42-2040622320942042
bibr4-2040622320942042
bibr50-2040622320942042
bibr48-2040622320942042
bibr27-2040622320942042
bibr14-2040622320942042
bibr11-2040622320942042
bibr24-2040622320942042
bibr1-2040622320942042
bibr45-2040622320942042
bibr32-2040622320942042
bibr19-2040622320942042
bibr15-2040622320942042
bibr23-2040622320942042
bibr40-2040622320942042
bibr2-2040622320942042
bibr31-2040622320942042
bibr22-2040622320942042
bibr16-2040622320942042
bibr3-2040622320942042
bibr25-2040622320942042
bibr13-2040622320942042
bibr30-2040622320942042
bibr17-2040622320942042
bibr26-2040622320942042
bibr39-2040622320942042
bibr18-2040622320942042
bibr12-2040622320942042
bibr20-2040622320942042
bibr33-2040622320942042
bibr46-2040622320942042
bibr41-2040622320942042
bibr5-2040622320942042
bibr49-2040622320942042
bibr36-2040622320942042
References_xml – volume: 70
  start-page: 151
  year: 2019
  end-page: 171
  article-title: Burden of liver diseases in the world
  publication-title: J Hepatol
– volume: 54
  start-page: 142
  year: 2005
  end-page: 151
  article-title: Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis
  publication-title: Gut
– volume: 273
  start-page: 33533
  year: 1998
  end-page: 33539
  article-title: Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant
  publication-title: J Biol Chem
– volume: 554
  start-page: 544
  year: 2018
  end-page: 548
  article-title: TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
  publication-title: Nature
– volume: 112
  start-page: 152
  year: 2003
  end-page: 159
  article-title: Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis
  publication-title: J Clin Invest
– volume: 254
  start-page: 120
  year: 2008
  end-page: 129
  article-title: Hepatic fibrosis – overview
  publication-title: Toxicology
– volume: 29
  start-page: 196
  year: 2011
  end-page: 202
  article-title: TGF-beta signaling in fibrosis
  publication-title: Growth Factors
– volume: 279
  start-page: 23996
  year: 2004
  end-page: 24006
  article-title: Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells
  publication-title: J Biol Chem
– volume: 8
  year: 2019 1419
  article-title: TGF-beta in hepatic stellate cell activation and liver fibrogenesis-updated 2019
  publication-title: Cells
– volume: 64
  start-page: 157
  year: 2016
  end-page: 167
  article-title: TGF-beta/SMAD pathway and its regulation in hepatic fibrosis
  publication-title: J Histochem Cytochem
– volume: 41
  start-page: 307
  year: 2005
  end-page: 314
  article-title: Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis
  publication-title: Hepatology
– volume: 287
  start-page: 1178
  year: 2012
  end-page: 1188
  article-title: Cathepsin B overexpression due to acid sphingomyelinase ablation promotes liver fibrosis in Niemann-Pick disease
  publication-title: J Biol Chem
– volume: 21
  start-page: S84
  year: 2006
  end-page: S87
  article-title: Hepatic stellate cells and the reversal of fibrosis
  publication-title: J Gastroenterol Hepatol
– volume: 2017
  start-page: 25
  year: 2017
  end-page: 35
  article-title: Metalloproteinases in liver fibrosis: current insights
  publication-title: Metalloproteinases In Medicine
– volume: 55
  start-page: 1353
  year: 2011
  end-page: 1360
  article-title: A role for autophagy during hepatic stellate cell activation
  publication-title: J Hepatol
– volume: 347
  start-page: 245
  year: 2012
  end-page: 256
  article-title: TGF-beta in progression of liver disease
  publication-title: Cell Tissue Res
– volume: 37
  start-page: 87
  year: 2003
  end-page: 95
  article-title: Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis
  publication-title: Hepatology
– volume: 283
  start-page: 2219
  year: 2016
  end-page: 2232
  article-title: TGF-beta signalling and liver disease
  publication-title: FEBS J
– volume: 18
  start-page: 613
  year: 2019
  end-page: 620
  article-title: TGFbeta blockade augments PD-1 inhibition to promote T-cell-mediated regression of pancreatic cancer
  publication-title: Mol Cancer Ther
– volume: 17
  start-page: 192
  year: 2018
  end-page: 197
  article-title: Hepatic fibrosis: it is time to go with hepatic stellate cell-specific therapeutic targets
  publication-title: Hepatobiliary Pancreat Dis Int
– volume: 92
  start-page: 1635
  year: 2010
  end-page: 1643
  article-title: Pathophysiological functions of cathepsin D: targeting its catalytic activity versus its protein binding activity?
  publication-title: Biochimie
– volume: 3
  start-page: 53
  year: 2015
  end-page: 66
  article-title: Animal models for fibrotic liver diseases: what we have, what we need, and what is under development
  publication-title: J Clin Transl Hepatol
– volume: 38
  start-page: 873
  year: 2017
  end-page: 898
  article-title: The future of cysteine cathepsins in disease management
  publication-title: Trends Pharmacol Sci
– volume: 68–69
  start-page: 463
  year: 2018
  end-page: 473
  article-title: Matrix metalloproteinases and liver fibrosis (translational aspects)
  publication-title: Matrix Biol
– volume: 46
  start-page: 955
  year: 2007
  end-page: 975
  article-title: Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies
  publication-title: J Hepatol
– volume: 70
  start-page: 985
  year: 2019
  end-page: 998
  article-title: Autophagy in liver diseases: time for translation?
  publication-title: J Hepatol
– volume: 21
  start-page: 437
  year: 2001
  end-page: 451
  article-title: Hepatic stellate cells as a target for the treatment of liver fibrosis
  publication-title: Semin Liver Dis
– volume: 289
  start-page: 16239
  year: 2014
  end-page: 16251
  article-title: Regulation of TGF-beta1-driven differentiation of human lung fibroblasts: emerging roles of cathepsin B and cystatin C
  publication-title: J Biol Chem
– volume: 49
  start-page: 1297
  year: 2009
  end-page: 1307
  article-title: Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential
  publication-title: Hepatology
– volume: 22
  start-page: 72
  year: 2016
  end-page: 88
  article-title: Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance
  publication-title: World J Gastroenterol
– volume: 8
  start-page: 126
  year: 2012
  end-page: 128
  article-title: Autophagy: a new player in hepatic stellate cell activation
  publication-title: Autophagy
– volume: 12
  start-page: 325
  year: 2016
  end-page: 338
  article-title: TGF-beta: the master regulator of fibrosis
  publication-title: Nat Rev Nephrol
– volume: 276
  start-page: 19945
  year: 2001
  end-page: 19953
  article-title: Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts
  publication-title: J Biol Chem
– volume: 9
  start-page: 11145
  year: 2018
  end-page: 11158
  article-title: Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
  publication-title: Oncotarget
– volume: 36
  start-page: 615
  year: 2002
  end-page: 622
  article-title: Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloproteinase-2
  publication-title: Hepatology
– volume: 79
  start-page: 903
  year: 2019
  end-page: 927
  article-title: Fibrosis in chronic liver disease: an update on diagnostic and treatment modalities
  publication-title: Drugs
– volume: 21
  start-page: S88
  year: 2006
  end-page: S91
  article-title: Matrix metalloproteinases, the pros and cons, in liver fibrosis
  publication-title: J Gastroenterol Hepatol
– volume: 121
  start-page: 27
  year: 2017
  end-page: 42
  article-title: Hepatic stellate cells as key target in liver fibrosis
  publication-title: Adv Drug Deliv Rev
– volume: 7
  start-page: 9289
  year: 2017
  article-title: Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-beta1/Smads and PI3K/Akt pathways
  publication-title: Sci Rep
– volume: 1
  start-page: 1255
  year: 1999
  end-page: 1263
  article-title: TGF-beta: from latent to active
  publication-title: Microbes Infect
– volume: 56
  start-page: 284
  year: 2007
  end-page: 292
  article-title: Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis
  publication-title: Gut
– volume: 7
  start-page: d793
  year: 2002
  end-page: d807
  article-title: Roles of TGF-beta in hepatic fibrosis
  publication-title: Front Biosci
– volume: 66
  year: 2014
  article-title: The DEN and CCl4 -induced mouse model of fibrosis and inflammation-associated hepatocellular carcinoma
  publication-title: Curr Protoc Pharmacol
– volume: 396
  start-page: 111
  year: 2015
  end-page: 130
  article-title: Cysteine cathepsins and cystatins: from ancillary tasks to prominent status in lung diseases
  publication-title: Biol Chem
– volume: 44–46
  start-page: 247
  year: 2015
  end-page: 254
  article-title: The role of TIMPs in regulation of extracellular matrix proteolysis
  publication-title: Matrix Biol
– volume: 142
  start-page: 938
  year: 2012
  end-page: 946
  article-title: Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues
  publication-title: Gastroenterology
– volume: 17
  start-page: 19
  year: 2006
  end-page: 27
  article-title: Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis
  publication-title: Cytokine Growth Factor Rev
– volume: 29
  start-page: 966
  year: 2009
  end-page: 978
  article-title: Active matrix metalloproteinase-2 promotes apoptosis of hepatic stellate cells via the cleavage of cellular N-cadherin
  publication-title: Liver Int
– article-title: GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma
  publication-title: Invest New Drugs
– volume: 90
  start-page: 1025
  year: 2016
  end-page: 1048
  article-title: Experimental models of liver fibrosis
  publication-title: Arch Toxicol
– ident: bibr4-2040622320942042
  doi: 10.1016/j.hbpd.2018.04.003
– ident: bibr43-2040622320942042
  doi: 10.1111/j.1440-1746.2006.04584.x
– ident: bibr41-2040622320942042
  doi: 10.1002/hep.22753
– ident: bibr20-2040622320942042
  doi: 10.1016/j.jhep.2011.07.010
– ident: bibr38-2040622320942042
  doi: 10.1074/jbc.M102382200
– ident: bibr47-2040622320942042
  doi: 10.1074/jbc.M311668200
– ident: bibr9-2040622320942042
  doi: 10.18632/oncotarget.24298
– ident: bibr8-2040622320942042
– ident: bibr13-2040622320942042
  doi: 10.1016/j.tips.2017.06.003
– ident: bibr26-2040622320942042
  doi: 10.1016/j.tox.2008.06.013
– ident: bibr35-2040622320942042
  doi: 10.1016/j.jhep.2019.01.026
– ident: bibr51-2040622320942042
  doi: 10.1038/nature25501
– ident: bibr6-2040622320942042
  doi: 10.3748/wjg.v22.i1.72
– ident: bibr22-2040622320942042
  doi: 10.1369/0022155415627681
– ident: bibr29-2040622320942042
  doi: 10.3390/cells8111419
– ident: bibr36-2040622320942042
  doi: 10.1515/hsz-2014-0210
– ident: bibr1-2040622320942042
  doi: 10.1016/j.jhep.2018.09.014
– ident: bibr39-2040622320942042
  doi: 10.1074/jbc.M111.272393
– ident: bibr44-2040622320942042
  doi: 10.1016/j.matbio.2017.12.012
– ident: bibr45-2040622320942042
  doi: 10.2147/MNM.S124363
– ident: bibr48-2040622320942042
  doi: 10.1111/j.1478-3231.2009.02070.x
– ident: bibr14-2040622320942042
  doi: 10.1016/j.biochi.2010.05.009
– ident: bibr19-2040622320942042
  doi: 10.1038/s41598-017-09673-5
– ident: bibr30-2040622320942042
  doi: 10.1002/hep.20538
– ident: bibr46-2040622320942042
  doi: 10.1111/j.1440-1746.2006.04586.x
– ident: bibr40-2040622320942042
  doi: 10.1172/JCI200317740
– ident: bibr50-2040622320942042
  doi: 10.1158/1535-7163.MCT-18-0850
– ident: bibr27-2040622320942042
  doi: 10.1136/gut.2005.088690
– ident: bibr5-2040622320942042
  doi: 10.1007/s40265-019-01126-9
– ident: bibr33-2040622320942042
  doi: 10.1007/s00204-015-1543-4
– ident: bibr37-2040622320942042
  doi: 10.1016/j.cytogfr.2005.09.008
– ident: bibr23-2040622320942042
  doi: 10.1007/s00441-011-1246-y
– ident: bibr42-2040622320942042
  doi: 10.1016/j.matbio.2015.03.005
– ident: bibr31-2040622320942042
  doi: 10.1002/0471141755.ph1430s66
– ident: bibr18-2040622320942042
  doi: 10.1053/j.gastro.2011.12.044
– ident: bibr28-2040622320942042
  doi: 10.1016/j.jhep.2007.02.003
– ident: bibr2-2040622320942042
  doi: 10.1016/j.addr.2017.05.007
– ident: bibr12-2040622320942042
  doi: 10.1074/jbc.273.50.33533
– ident: bibr34-2040622320942042
  doi: 10.4161/auto.8.1.18105
– ident: bibr21-2040622320942042
  doi: 10.1038/nrneph.2016.48
– ident: bibr10-2040622320942042
  doi: 10.1136/gut.2004.042127
– ident: bibr49-2040622320942042
  doi: 10.1053/jhep.2002.35279
– ident: bibr25-2040622320942042
  doi: 10.2741/A812
– ident: bibr16-2040622320942042
  doi: 10.3109/08977194.2011.595714
– ident: bibr3-2040622320942042
  doi: 10.1055/s-2001-17558
– ident: bibr17-2040622320942042
  doi: 10.1074/jbc.M113.542407
– ident: bibr7-2040622320942042
  doi: 10.1007/s10637-019-00741-3.
– ident: bibr11-2040622320942042
  doi: 10.1053/jhep.2003.50002
– ident: bibr15-2040622320942042
  doi: 10.1016/S1286-4579(99)00259-2
– ident: bibr24-2040622320942042
  doi: 10.1111/febs.13665
– ident: bibr32-2040622320942042
  doi: 10.14218/JCTH.2014.00035
SSID ssj0000463348
Score 2.2080624
Snippet Background: Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no...
Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no anti-fibrotic drugs...
Background: Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no...
SourceID doaj
pubmedcentral
hal
proquest
pubmed
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2040622320942042
SubjectTerms Autophagy
Biochemistry, Molecular Biology
Cellular biology
Inhibitor drugs
Life Sciences
Liver
Liver cirrhosis
Liver diseases
Original Research
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LbtQw0IIiIS6INykFGYSQOEQbv-LkhApiu0K0F1ppb1HsON2IVbI020r8Fh_CNzHj9WYJFZVySMZOYo1nPA-PZwh5q5OsZFLlsc2MiKVJk7h0dRLLiiWVzIXLHR5wPj5JZ2fyy1zNg8OtD2GV2zXRL9RVZ9FHPgExxFWGFeQ-rH7EWDUKd1dDCY3b5I5PXQb0rOd68LFgNizhC2hxDJxLQRTudionCEMQBwsH7vlIMvkE_iBvFhgeeV33vB5C-VccmBdN0wfkftAp6eGGCB6SW659RO4eh13zx-T70ck3UGBoadc9LeGiqw5U5TUFrDZxDQZzB2_CU0VhCBvA8qcH4cEr2rR0ieEb1Lf0TU9DdR96ejSNf_9i0GPRGB_89YScTT-ffprFochCbCVo1jHwrxVVnTqNAW8axX-V5tIqCxi3YO5pw7XJDJgVQuk8Y7qUysjMMmZNaUvxlOy1XeueEwq4LHnFay1qJUtVwfoFGohl1nFdgdyLyGSL4MKGDORYCGNZsJB0_N8picj74Y3VJvvGDX0_4pwN_TBvtgd0F-dFYMOC1dzKWtUWc-Qoboyywsiq5sIBjKUReQMzPvrG7PBrgTCs8qUBW1csIgdbgigCx_fFjj4j8npoBl7FDZiydd0l9uF5ojJY9SLybEM_w68E16ApsCQiekRZo7GMW9pm4fOBa5GmYCZH5B3S4G5I_8PU_s3jf0HucXQqeD_TAdlbX1y6l6B5rc0rz15_ANZNI00
  priority: 102
  providerName: ProQuest
– databaseName: Open Access资源_Sage Open Access Journals @sage主站点
  dbid: AFRWT
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1db9NAzBqbhHhBfBMY6EAIiYdjua9c8oQKoqsQ2wN0Ym9R7pLQii6Z1hZpf4sfwm_CztcoFQgpD43v0jv57LN99tkAL2wYZ0KbhPvYKa5dFPKsKEOucxHmOlFFUtAF56PjaHKiP5ya0x2o-rswHQaXrymsCmfUbNbE3XQafdA5GdFiRzmEgk2icYK_5Zv16ixtT7v7ohoEIff0-ow8257iIS95f7vtGuxRLSZk5L3R-NOX6XAqQ_mzVFNyi4bgNMaVb3Nr2A1Z1qT8Rwk1o4DKbW11O-jyt8ixRpiNb8HNTgtlo5ZsbsNOUd2B60edn_0ufDs8_owqD8v8askyfNh5jcr1iuE6zHmJJnaNX-JbznAKLWBx2YDoqhabV2xBAR-saVnOl6yrB8Smh2P-84fAHrO5a8LF7sHJ-P303YR3ZRm416iLc-R4r_IyKiyFyFlSGPIo0d54VBU8GojWSetih4aIMjaJhc20cTr2QniX-Uzdh92qroqHwBCXmcxlaVVpdGZy3PFQZ_HCF9LmKCkDOOgRnPouZzmVzlikoktT_ueSBPBq-OK8zdfxj75vac2GfpRpuwHUF1_TjnFTUUqvS1N6yqpjpHPGK6fzUqoCYSIK4Dmu-MZ_TEYfU4JRXTCL2PouAtjvCSLtKTxFbEkTU03EAJ4Nzcjd5LLJqqJeUx-ZhCbGfTKABy39DEMpaVG3EGEAdoOyNuay2VLNZ00GcauiCA3rAF4SDV5N6W-YevS_HR_DDUkHEs0Z1T7sri7WxRPU2lbuacdqvwDFbTZO
  priority: 102
  providerName: SAGE Publications
Title GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition
URI https://journals.sagepub.com/doi/full/10.1177/2040622320942042
https://www.ncbi.nlm.nih.gov/pubmed/32728410
https://www.proquest.com/docview/2442581874
https://www.proquest.com/docview/2429058319
https://univ-tours.hal.science/hal-02977880
https://pubmed.ncbi.nlm.nih.gov/PMC7366401
https://doaj.org/article/1f2c4f5fc156452bb5c3b4df23efc116
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fa9swED-2DsZeyv7PWxe0MQZ7MLX-WfZjOpqGsYbRpSxvRpJlYhac0qSDfq1-kH2mnWQ3jVe2vQwCTk7nWJxOujvr9DuAdyrJNBUyj21meCxMmsTaVUksSpqUIucud_6A8_EkHZ-KTzM52yr15XPCWnjgVnD7tGJWVLKyHtVEMmOk5UaUFeMOaTSAbSd5shVMhTVYpP6I6c2-JAb5aLrQFiKzwO-sZ4cCXD9al7lPhrztad5OmNzK-gqGaPQQdjsPkgzbnj-CO655DPePuz3yJ_D9aPIV3RWi7XpFNH7I2RId4zVBGdZxheHxEu_EXyXBLrSExWUg-WNWpG7IwidrkNCyqlekq-VDpkej-OcVRY55bUKq11M4HR1OP47jrqRCbAX60THOVsvLKnXKp7cpb-zLNBdWWjTzFoM7ZZgymcEggkuVZ1RpIY3IUNLWaKv5M9hplo17AQRlqVnJKsUrKbQscbVCf8NS65gq0cpFsH8t4MJ2eOO-7MWioB3E-O9DEsGHzR1nLdbGX3gP_Jht-DxKdiCg7hSd7hT_0p0I3uKI9_5jPPxceJqv6aVQWj9oBHvXClF083tVoLSYzHw9wwjebJpxZvrtFt245YXnYXkiM1zjInje6s_mUZwp9AtoEoHqaVavL_2Wpp4H9G_F0xSD4gjeex286dKfJPXyf0jqFTxg_kVDePe0Bzvr8wv3Gr2xtRnAXTVTA7g3HJ18m-L14HDy5WQQpuMvDkwu3g
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1db9Mw8DQ6CXhBfBMYYBAg8RA1duw4eUBog3UdaysEnbS3LHYSWlElZe1A-1M88EP4TdwlaUuZ2NukPCRnx7Z85_uwz3cAL7QXJlyqyLWh8V1pAs9NstxzZcq9VEZ-FmV0wbk_CLqH8sOROtqAn4u7MORWueCJFaNOS0t75G0UQ0KFlEHu7fSbS1mj6HR1kUKjJouD7OwHmmyzN_vvEb8vhejsDt913SargGslqpIuEqz10zzINHl4aZJ3aRBJqyx2YdG-0UZoExrUo32lo5DrRCojQ8u5NYlNfGz3CmxKutHags2d3cHHT8tdHYq_5VcpuwS56gUofFdno22CEUigTYXvYk0WVikDUMKNyCHzvLZ73mnzL8-zShh2bsKNRotl2zXZ3YKNrLgNV_vNOf0d-Lo3-IwqE0vsfMYSfNi0ROV8zhCPYzdHE73EP_ErZTiEGjA5q0B01YuNCzYhhxFWlczGM9bkE2LDvY77-xfHGqOxqdzN7sLhpSDgHrSKssgeAMO5TEQqcu3nSiYqRY6JOo_lNhM6RUnrQHsxwbFtYp5T6o1JzJsw5_-ixIHXyz-mdbyPC-ruEM6W9ShSdwUoT77EzcKPeS6szFVuKSqPEsYo6xuZ5sLPEMYDB54jxtfa6G73YoJRXjGNs_WdO7C1IIi44TGzeLUiHHi2LEbuQEc-SZGVp1RHRJ4Kkc86cL-mn2VXvtCom3DPAb1GWWtjWS8pxqMqArn2gwANcwdeEQ2uhvS_mXp48fifwrXusN-Le_uDg0dwXdCWRrXLtQWt-clp9hj1vrl50iw2BseXvb7_AMTXXyA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1db9NAzEKdNPGCGJ-BAQdCSDyE5b5yyWP56ApsFYJO7C3KXZK1okqrtZvE3-KH8Juw02tGqEBIeWh8vvTks8_2nc8GeG6iJOdKp6FLrAyVjaMwL6soVAWPCpXKMi3pgvPxKB6eqA-n-tTH5tBdGE_B5SsKq8IRNYs1SfeiqA78GSM67KiGUK8J9E3wN67AO4pK6PZgpz_4_HXcbrJQOizZVNCiLiH1uTqq3PpMRzU1GfxR4UwoPnLb-NyOofwtEKzRTYObcMMblay_5oI9uFbWt2D32B-b34Zvh6MvaMGw3K2WLMeHLeZoK68YknUaVugxz7EnvhUMh7AGzL43ILp5xaY1m1H8BmtaltMl8-V92PhwEP78wRFjMrVN9NcdOBm8G78Zhr7KQugUmtYhCrCTRRWXhiLeDOn_Ik6V0w41v0N_z1hhbGLRr5DapAk3udJWJY5zZ3OXy7vQq-d1eR8Y0jIXhaiMrLTKdYELGJogjrtSmAIVXwAHGwJnzqcgp0oYs4z7rON_TkkAL9sei3X6jX_gvqY5a_EocXYDmJ-fZV4OM14JpypdOUqSo4W12kmrikrIEmE8DuAZznjnG8P-UUYwKvNlkFqXPID9DUNkG4bNkFpCJ1TiMICnbTMKK53A5HU5vyAckUY6wWUvgHtr_mn_SgqDpgKPAjAdzuqMpdtSTydNQnAj4xj95ABeEA9eDelvlHrwv4hPYPfT20F29H708SFcF7TV0Ow-7UNvdX5RPkJ7bGUfe6n7BXwaJM0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=GNS561+acts+as+a+potent+anti-fibrotic+and+pro-fibrolytic+agent+in+liver+fibrosis+through+TGF-%CE%B21+inhibition&rft.jtitle=Therapeutic+advances+in+chronic+disease&rft.au=Bestion%2C+Elo%C3%AFne&rft.au=Jilkova%2C+Zuzana+Macek&rft.au=M%C3%A8ge%2C+Jean-Louis&rft.au=Novello%2C+Marie&rft.date=2020&rft.issn=2040-6223&rft.volume=11&rft.spage=2040622320942042&rft_id=info:doi/10.1177%2F2040622320942042&rft_id=info%3Apmid%2F32728410&rft.externalDocID=32728410
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2040-6223&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2040-6223&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2040-6223&client=summon